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Objective: With improvements in hematopoietic cell transplanta-
tion (HCT) for severe aplastic anemia (SAA), there is a growing pop-
ulation of SAA survivors of HCT. However, there is a paucity of
information regarding late effects in SAA HCT survivors. We ana-
lyzed the burden of malignant and non-malignant late effects in
HCT survivors with acquired SAA.
Methods: A descriptive analysis of 1,718 patients post-HCT for ac-
quired SAA between 1995-2006 reported to the CIBMTR was con-
ducted. Cumulative incidences (CI) of selected late effects are
reported for among ‘‘condition-free’’ (i.e. survivors without a previ-
ous diagnosis of the specified late effect) HCT survivors with SAA.
Results:One-year overall survival for the recipients of related donor
HCT was 83% (80-85) and 62% (58-66) for the recipients of unre-
lated donor HCT. Of the HCT recipients, 1176 (68.5%) patients
with a median age at HCT of 20 years (\1-65) utilized a related do-
nor and 542 (31.5%) patients with a median age at HCT of 20 years
(\1-67) utilized an unrelated donor. Themedian interval from diag-
nosis to transplant was 3 months (\1-348) for related donor HCT
and 14 months (1-318) for unrelated donor HCT. Radiation (of
any type) was utilized in 6% and 78% of related and unrelated donor
HCT cases; respectively. Cy-TBI (68%) was a commonly utilized
conditioning regimen for unrelated donor HCT. The median fol-
low-up is 70 months (1-160) and 67 months (3-182) for related
and unrelated donor HCT; respectively. The 2-year CI of chronic
GVHD was 20% (18-22) and 37% (32-41) in related and unrelated
donor HCT; respectively. Table 1 demonstrates that among 1-year
condition-free survivors, the CI of late effects is greater among un-
related donor HCT survivors and continues to increase.
Conclusion: These findings suggest that HCT survviors with SAA
are a robust and healthy group in general. However, subgroups of pa-
tients undergoing HCT for SAA are at-risk for late effects and must
be educated about and should be monitored for late effects. Sub-
groups of survivors may be at-risk group for a greater burden of spe-S226cific late effects. Ongoing analyses in our cohort will explore selected
risk-factors for late effects after HCT for SAA.
Table 1. Interval specific cumulative incidence of select late
effects among 1-year condition free survivors following related
and unrelated donorHCT for acquired SAAbetween 1995 and
2006 reported to the CIBMTR
Related Donor Unrelated DonorHealth conditions
post transplantN
(at risk)N
(at risk)Cumulative
Incidence % (95% CI)Cumulative
Incidence % (95% CI)Strokes/SeizuresOver next 2 years 707 1.7 (0.9-2.7) 283 1.3 (0.3-2.8)Over next 5 years 416 1.8 (1.0-2.9) 118 2.8 (1.2-5.1)Gonadal DysfunctionOver next 2 years 709 2.6 (1.6-3.8) 273 6.2 (3.8-9.1)Over next 5 years 419 3.0 (2.0-4.3) 108 10.5 (7.3-14.3)Renal FailureOver next 2 years 715 1.1 (0.5-1.9) 287 1.9 (0.7-3.6)Over next 5 years 425 1.4 (0.7-2.3) 127 2.4 (0.9-4.5)Avascular NecrosisOver next 2 years 724 1.4 (0.7-2.3) 276 3.2 (1.5-5.4)Over next 5 years 426 1.8 (1.0-2.8) 117 6.3 (3.6-9.7)CataractsOver next 2 years 734 0.6 (0.2-1.2) 284 2.2 (0.9-4.1)Over next 5 years 433 1.1 (0.5-1.9) 118 5.1 (2.9-8.0)Growth DisturbanceOver next 2 years 735 0.2 (0.0-0.7) 286 1.9 (0.7-3.6)Over next 5 years 433 0.5 (0.1-1.2) 113 7.2 (4.4-10.7)HypothyroidismOver next 2 years 731 0.7 (0.3-1.4) 286 0.6 (0.1-1.8)Over next 5 years 432 1.2 (0.5-2.1) 119 5.5 (2.8-9.0)Solid TumorsOver next 2 years 820 0.6 (0.2-1.1) 276 0.7 (0.1-1.9)Over next 5 years 528 0.7 (0.2-1.3) 121 1.4 (0.4-3.0)64
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Purpose: To determine the influence of concurrent metabolic con-
ditions and lifestyle factors on the risk of cardiovascular (CV) disease
following hematopoietic cell transplantation (HCT).
Methods: HCT survivors treated at the Fred Hutchinson Cancer
Research Center from 1970-2010 were surveyed with respect to se-
lected serious CV outcomes, related metabolic conditions requiring
medications, obesity, lifestyle factors (smoking, physical activity,
diet), and family history beginning in July 2010 (ongoing) using pre-
viously validated self-report questionnaires.
Results: Among 1489 respondents (47% female, median age 57
years, median time since HCT 9 years, 68% allogeneic, 40% with
history of chronic graft versus host disease (GVHD)), the incidence
of serious CV outcomes following HCT included cardiomyopathy
(3.4%), ischemic heart disease (4.4%), and cerebrovascular disease
(4.9%). The prevalence of related metabolic conditions included hy-
pertension (33.8%), dyslipidemia (34.4%), and diabetes (11.8%).
32.8% of patients were currently overweight and 16.4% obese, while
32.1% had a prior history of smoking and 6.3% reported current
smoking. Inmultivariate analyses adjusting forGVHDstatus, hyper-
tension was associated with an increased likelihood of cardiomyopa-
thy (OR1.9, 95%CI 1.0-3.5), while dyslipidemia was associated with
increased likelihoods of ischemic heart disease (OR 3.9, 95%CI 2.1-
7.2) and cerebrovascular disease (OR 2.0, 95%CI 1.2-3.4). Diabetes,
obesity, and smoking (prior or current) were not independently asso-
ciated with any of these serious CV outcomes. Among respondents
free of serious CV disease, healthier diets (ORs 0.5-0.7; p\0.05)
Oral Presentations S227and increased physical activity (ORs 0.8-0.9; p5 0.04-0.07) were as-
sociated with a lower likelihood of requiring dyslipidemia or diabetes
medications. Obesity was significantly associated with an increased
likelihood of all 3 metabolic conditions (ORs 2.6-2.9; p\0.05). A
family history of CV disease also remained a significant risk factor
for most serious and related CV outcomes post-transplant.
Conclusions:HCT survivors have a high burden of metabolic con-
ditions (hypertension, dyslipidemia, diabetes, and obesity) known to
predispose towards more serious CV conditions following HCT. A
less healthy diet, decreased physical activity, and obesity were asso-
ciated with these conditions, suggesting potential interventions
that may reduce CV disease among HCT survivors.65
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OLDER ADULTS PRIOR TO ALLOGENEIC STEM CELL TRANSPLANTATION
(allo-HCT) IS INDEPENDENTLY ASSOCIATEDWITHWORSE TRANSPLANT
OUTCOMES
Muffly, L.S.1, Swanson, K.1, Boulukos, M.1, Kocherginsky, M.2, del
Cerro, P.1, Godley, L.A.1, Kline, J.1, Larson, R.A.1, Odenike, O.1,
Pape, L.1, Schroeder, L.1, Stock, W.1, Van Besien, K.1, Artz, A.S.1 1Uni-
versity of Chicago, Chicago, IL; 2University of Chicago, Chicago, IL
Introduction: Concern regarding baseline health status and ability
to predict tolerance have been major factors limiting application of
allo-HCT to older adults. Standard health status assessment tools
such as comorbidity and performance status (PS), have uncertain
prognostic significance in older transplant patients. Little is known
about health related QoL in older adults undergoing allo-HCT,
and how patient perceived physical and mental functioning relates
to transplant outcomes.
Methods:We performed a prospective comprehensive geriatric as-
sessment (CGA) on patients $50 years old prior to allo-HCT. As
part of CGA, 163 patients completed a Medical Outcomes Study
Short Form (SF-36), an extensively validated health related QoL
questionnaire. Physical and mental component summary measures
(PCS andMCS) were compared to population age group norms. Ka-
plan-Meier and Cox Regression analyses were used to determine the
association between PCS and MCS as continuous variables to non-
relapse mortality (NRM) and OS. To estimate effect size, we
modeled the hazard ratio (HR) for scores \40, which represents
1SD below population norm and approximated sample median.
Results:Median age was 58; 39% were.60. AML or MDS was the
most common diagnosis (53%); 48% had active disease (not in re-
mission) prior to allo-HCT. Donor sources were matched sibling
(45%), MUD (36%), mismatch/cord (19%). Conditioning was pri-
marily reduced intensity (75% vs 25% ablative). 44% had an
HCT-CI$3; 36% had ECOG PS $1. Pre-transplant SF-36 scores
demonstrated significantly worse physical and mental health com-
pared to age group matched controls (Table 1). Lower PCS and
MCS showed borderline association with increased NRM (P5 .076
for PCS; P 5 .05 for MCS). A stronger association existed for in-
ferior survival for lower PCS (P5 .002) and MCS (P5 .014), which
remained significant when controlling for age, disease risk, co-
morbidity, and PS. PCS and MCS scores\40 reduced OS by ap-
proximately 50% (HR 1.5, 95% CI 1.03-2.3, P 5 .03 for PCS; HR
1.47, 95% CI .97-2.2, P 5 .07 for MCS).
Conclusions: Self reported physical and mental health impairments
are frequent and substantial in older adults prior to allo-HCT.
Lower physical and mental health functioning independently con-
ferred inferior OS. Patient reported functional and mental health
deficits prior to transplantation warrant study as simple and novel
prognostic markers.
Table 1. PCS and MCS Scores By Age Group
PCS PCS MCS MCSAge
Population
Mean
Sample
Mean p-valuePopulation
MeanSample
Mean p-value45-54 (n 5 46) 49.62 41.91 <.0001 50.54 38.10 <.0001
55-64 (n 5 96) 47.44 41.43 <.0001 51.71 38.06 <.0001
65-74 (n 5 24) 44.70 43.30 .52 53.17 35.94 <.000166
LONG-TERM SURVIVAL AND QUALITY OF LIFE (QoL) ASSESSMENT AFTER
REDUCED INTENSITY CONDITIONING ALLOGENEIC STEM-CELL TRANS-
PLANTATION (SCT) FOR HEMATOLOGICAL MALIGNANCIES
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Allogeneic SCT is associated with substantial mortality during the
first 2 years after SCT whereas after 2 years survival reaches plateau.
QoL is increasingly recognized as an important long-term end-
point. The pattern of late events and QoL has been reported follow-
ing myeloablative conditioning (MAC) but is not well defined after
reduced intensity conditioning (RIC). To explore late outcomes
we retrospectively analyzed data of 726 patients (pts) given SCT be-
tween 1/2000 and 8/2009. 246 pts were alive and disease-free 2 years
after SCT, median age 51 years (17-72). Conditioning was MAC (n
5 72), RIC (n 5 118) or reduced-toxicity myeloablative condition-
ing (RTC, n 5 56). 44 and 29% of MAC and RIC/RTC recipients
had moderate-severe (mod-sev) cGVHD (p 5 0.03) while 68 and
43% were still on immune suppressive therapy (IST) 2 years after
SCT, respectively (p5 0.001).With median follow-up of 68 months
after SCT (25-140), the probability of pts surviving disease-free 2
years after SCT to remain alive and disease-free for the next 5 years
was 84 and 82% after MAC and RIC/RTC, respectively (p 5 NS).
There were 35 deaths beyond 2 years. 20 late deaths were NRM, cu-
mulative incidence 7% after both MAC and RIC/RTC. More MAC
pts died of cGVHD/ infections (6.9 Vs 2.3%, p 5 0.08) while more
RIC/RTC pts died of second cancers (4.6 Vs 1.4%, p5NS). 24 pts
relapsed, 25-102 months after SCT, cumulative incidence 9% after
MAC and 11% after RIC/RTC (p 5 NS); 15 died. Age.55 and
mod-sev chGVHD predicted shorter survival, HR 2.1 (p 5 0.07)
and 2.6 (p 5 0.006), respectively. Mod-sev cGVHD predicted
NRM, HR 5.2 (p 5 0.001). Advanced disease predicted relapse,
HR 2.6 (p 5 0.004). Conditioning regimen was not predictive for
any of these outcomes. The probability of stopping IST by 8 years
was 59 and 75% after MAC and RIC/RTC, respectively (p 5
0.001). The median duration of IST was 30 and 20 months, respec-
tively (p5 0.05). QoLwas assessed by the EORTCQLQ-C30 ques-
tionnaire. Mean QoL score was 69, 66 and 65 after MAC, RIC and
RTC, respectively. LowQoL score was reported by 15, 14 and 19%,
respectively (p5NS).Multiple regression analysis identified contin-
uous need for IST and depression as factors correlated with a low
score while healthy lifestyle (return to work, physical and sexual ac-
tivity) and academic education correlated with high scores. In con-
clusion, late outcome is similar after MAC and RIC/RTC. Late
NRM and QoL is similar although cGVHD is less severe and IST
duration shorter after RIC/RTC.67
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Introduction: Many long-term survivors of hematopoietic cell
transplantation (HCT) struggle with health needs. The internet
may be an optimal way to reach these survivors since it can be indi-
vidualized and accessible as needed. Little is known about internet
site reach and utilization in HCT survivors. Determining the repre-
sentation of those who enroll and use an internet site is essential to
effective dissemination of these programs.
Method: All 3-18 yearHCT survivors treated at a single center were
approached for enrollment in a randomized controlled trial if they
were 18 or older, lived in the United States or Canada, had been
treated for a hematologic malignancy, their medical records did not
indicate a relapse or second cancer in the previous two years, they
had internet access, an email address and adequate English skills to
complete the assessment. Survivorswere randomly assigned to imme-
diate internet site access or delayed access after 6-month outcomes.
Results: Of 1311 approached and eligible for the study, 755 (58%)
consented and completed baseline assessment. Participants were
